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Abstract
Background: Refractory and/or relapsed diffuse large B cell lymphoma (RR-DLBCL) patients are incurable with
conventional chemotherapy due to the aggressiveness and the chemorefractory state of these tumors. DNA
hypermethylation and histone deacetylation are two major epigenetic modifications by which aggressive DLBCL
maintain their oncogenic state. We have previously reported that DNA methyltransferase inhibitors (DNMTI) affect
RR-DLBCL growth and improve chemosensitivity. Here, we hypothesized that the combination of DNMTI with
histone deacetylase inhibitor (HDI) would be an active and feasible therapeutic strategy in RR-DLBCL. Thus, we
evaluated the anti-lymphoma activity of the HDI vorinostat (VST) in combination with the DNMTI azacitidine (AZA)
or decitabine (DAC) in pre-clinical models of RR-DLBCL, and we determined the feasibility of the combination by
conducting a phase Ib trial in RR-DLBCL patients.
Results: Concurrent combination of DNMTI and HDI resulted in synergistic anti-lymphoma effect toward RR-DLBCL
cells in vitro and in vivo, with no significant toxicity increase. In a phase Ib trial, a total of 18 patients with a median
of three prior therapies were treated with four different dose levels of AZA and VST. The most common toxicities
were hematological, followed by gastrointestinal and metabolic. The clinical benefit was low as only one subject
had a partial response and three subjects had stable disease. Interestingly, two of the seven patients that received
additional chemotherapy post-study achieved a complete response and three others had a significant clinical
benefit. These observations suggested that the combination might have a delayed chemosensitization effect that
we were able to confirm by using in vitro and in vivo models. These studies also demonstrated that the addition of
VST does not improve the chemosensitizing effect of DAC alone.
Conclusions: Our data supports the strategy of epigenetic priming by employing DNMTI in RR-DLBCL patients in
order to overcome resistance and improve their outcomes.
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Background
Diffuse large B cell lymphoma (DLBCL) is the most com-
mon form of non-Hodgkin lymphoma in adults. DLBCL
is an aggressive but potentially curable disease as roughly
60 % of patients obtain a complete and sustained response
with the standard chemo-immunotherapy treatment of
the anti-CD20 monoclonal antibody rituximab and four
chemotherapeutic agents (cyclophosphamide, doxorubi-
cin, vincristine, and prednisolone) (RCHOP) [1, 2]. Unfor-
tunately, the prognosis of patients with primary
chemotherapy refractory disease or those that relapse after
initial response remains poor. Response rates to second-
line chemotherapy regimens are roughly 50 % with long-
term survival rates of only 20 % despite aggressive
approaches such as autologous stem cell transplantation
[3]. Patients that do not respond to second-line therapy
have an average survival of only 4 months [4]. Thus, novel
approaches are needed for patients with relapsed or
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refractory DLBCL (RR-DLBCL). Epigenetic modifications
such as DNA methylation and histone acetylation orches-
trate the regulatory state of chromatin. Many cancers dis-
play global changes in histone modifications and aberrant
methylation patterns that allow them to sustain their
oncogenic state. Malignant cells repress the expression of
genes involved in tumor suppressive pathways mostly
through DNA hypermethylation and histone deacetyla-
tion. DNA methyltransferases (DNMT) and histone dea-
cetylases (HDAC) are the key enzymes leading this
process [5]. Since epigenetic silencing is a reversible
process, pharmacological inhibition of DNMTs and
HDACs has rapidly became an attractive therapeutic strat-
egy as it allows the restoration of those non-functional
pathways in tumor cells inducing phenotypic changes that
may lead to cell death. Interestingly, DLBCL patients with
more aggressive disease exhibit a greater degree of epigen-
etic aberrations [5, 6]. Moreover, our group has previously
demonstrated that administration of DNMT inhibitors
(DNMTI) induces reprogramming of refractory DLBCL
cells resulting in recovery of sensitivity toward DNA dam-
aging agents [7]. Overall, these data suggest that aggressive
RR-DLBCL may rely on epigenetic silencing of multiple
genes to survive as well as tolerate genotoxic stress. Epi-
genetic drugs such as HDAC inhibitors (HDI) and
DNMTI have shown to be well tolerated but with limited
activity in DLBCL patients [8, 9]. The modest activity of
these drugs as single agents suggests that pathways critical
for survival may be simultaneously regulated by different
epigenetic modifications in DLBCL. This hypothesis is
supported also by the observation that hypermethylated
CpG islands attract methyl-CpG-binding domain proteins
(MBDPs) and recruit HDACs, leading into an enhanced
transcriptional inhibition [10, 11]. Thus, the combination
of HDI and DNMTI may achieve a greater efficacy in dis-
rupting the transcription repressor complex composed by
MBDPs and HDACs. We therefore speculated that com-
binatorial targeting of HDAC and DNMT could (i) exert
synergistic cytotoxic effect on RR-DLBCL; (ii) be a
safe and active therapeutic strategy in patients with
aggressive RR-DLBCL; (iii) achieve a greater degree of
chemosensitization compared to DNMTI alone in RR-
DLBCL. Following this rationale, first we determined
if the combination of the DNMTI and HDI would
yield a better anti-lymphoma effect in pre-clinical
models of RR-DLBCL. We then evaluated the feasibil-
ity of this combinatorial treatment by conducting a
phase Ib study of the DNMTI 5-azacitidine (azaciti-
dine, AZA) with the HDI suberoylanilide hydroxamic
acid (vorinostat, VST) in patients with RR-DLBCL.
Finally, by using in vitro and in vivo pre-clinical
models, we explored whether the simultaneous inhib-




5-aza-2′-deoxycytidine (decitabine, DAC) was from
Dacogen, 5-azacitidine (azacitidine, AZA) was from
Aton Pharma, and suberoylanilide hydroxamic acid (vor-
inostat, VST) was from LC Laboratories. All three drugs
were dissolved in distilled water and used within an hour
of preparation.
Cell lines
Human DLBCL cell lines OCI-Ly1, OCI-Ly4, and OCI-
Ly7 were grown in medium containing 90 % Iscove’s
modified Eagle medium and 10 % fetal calf serum (FCS;
20 % FCS for OCI-Ly7) supplemented with 1 % penicil-
lin G and streptomycin. DLBCL cell lines DB, Farage,
HT, Karpas422, Karpas231, NU-DUL-1, OCI-Ly3, OCI-
Ly8, OCI-Ly18, OCI-Ly19, OZ, RL, RC-K8, RI-1, SU-
DHL4, SU-DHL5, SU-DHL6, SU-DHL7, SU-DHL8, SU-
DHL10, SC1, Toledo, VAL1, and WSU-NHL were grown
in medium containing 90 % RPMI-1640 and 10 % FCS
supplemented with 1 % penicillin G and streptomycin,
1 % L-glutamine, and 1 % HEPES. Cells were maintained
in a 37 °C, 5 % CO2, fully humidified incubator. All cell
lines were purchased from the American Type Culture
Collection, Leibniz Institute DMSZ-German Collection
of Microorganisms and Cell Cultures, or the Ontario
Cancer Institute. Monthly testing for Mycoplasma sp.
and other contaminants and quarterly cell identification
by single-nucleotide polymorphism were conducted.
Growth inhibition determination
All cell lines were grown at concentrations that assured
to maintain non-treated cells in exponential growth over
the drug exposure time. Cell viability was determined by
a fluorescence assay using resazurin (7-Hydroxy-3H-
phenoxazin-3-one 10-oxide) (CellTiter-Blue, Promega).
Fluorescence was measured in a Synergy4 microplate
reader (BioTek) employing 560 and 590 nm of excitation
and emission wavelengths, respectively. The number of
viable cells was calculated by using the linear least-
squares regression of the standard curve. The fluores-
cence emission was determined for three replicates per
treatment condition and normalized to their respective
controls (vehicle-treated cells). Dose-effect curves were
plotted, and GI50 values were determined using Graph-
Pad Prism version 6.0b software. Data were presented as
the mean GI50 with a 95 % confidence interval for du-
plicate experiments.
Drug combination analysis
Interaction between vorinostat and decitabine was evalu-
ated employing the combination index (CI) equation of
Chou and Talalay [12]: CI = (D1/Dx1) + (D2/Dx2). A CI
value equal to one indicates additivity, values less than
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one indicate synergy, and values greater than one indi-
cate antagonism. Doses D1 and D2 correspond to those
used in combination, and the doses Dx1 and Dx2 corres-
pond to the amounts of each drug given alone that
would produce the same response as obtained with the
combination. CI values were calculated employing Com-
puSyn software, and isobolograms were plotted using
GraphPad Prism version 6.0b software.
Mice studies
All mouse procedures were approved by The Research
Animal Resource Center of the Weill Cornell Medical
College of Medicine. Adult (6- to 8-week-old, male,
weighting average of 20 g) severe combined immuno-
deficiency (SCID) mice were purchased from the US Na-
tional Cancer Institute (NCI) and subcutaneously
injected in the left flank with 10 × 106 low-passage hu-
man RR-DLBCL OCI-Ly7 cells. Tumor size was moni-
tored every other day employing electronic digital
calipers. Tumor volume was calculated using the equa-
tion: tumor volume = (smallest diameter2 × largest diam-
eter)/2. Treatment schedules are described in the
“Results” section. Decitabine and vorinostat were dis-
solved in 100 % sterile water and 1:1 sterile water in
DMSO, respectively. Both drugs were administered in-
traperitoneally. The mice were weighed every other day.
At the end of the experiment, the mice were euthanized
by CO2 inhalation.
Clinical trial design
An open-label phase Ib study in patients with relapsed
or refractory DLBCL was approved by the Institutional
Review Board of Weill Cornell Medical College (Clini-
calTrials.gov identification number NCT01120834). The
primary objective was to determine the safety and toler-
ability of the combination of AZA (Celgene) with VST
(Merck) and to determine an appropriate dose for fur-
ther evaluation. Secondary objectives were to determine
the efficacy of this combination by measuring the overall
response rates (ORR) and overall survival (OS). We per-
formed a retrospective review of seven subjects who pro-
ceeded to have treatment post-study and evaluated their
ORR and subsequent OS following the study regimen.
Patients
Eligible patients were >18 years of age and had histologi-
cally confirmed RR-DLBCL. Patients had to have meas-
urable disease and had to be deemed ineligible for
autologous stem cell transplantation. There was no limit
on the number of prior therapies and previous autolo-
gous stem cell transplantation was allowed. Patients also
had to have an Eastern Cooperative Oncology Group
(ECOG) performance score ≤2, absolute neutrophil
count (ANC) ≥1000/μL, platelets ≥75/μL, and adequate
renal and hepatic function. Exclusion criteria included a
prior allogeneic transplant, previous HDAC inhibitors
for anti-lymphoma therapy, active central nervous sys-
tem (CNS) lymphoma, active second malignancy, uncon-
trolled illness, and a QTc interval of >0.470.
Treatment
AZA was administered via subcutaneous injection, and
VST was taken orally at four different dose levels (DL):
AZA 55 mg/m2 days 1–5 and VST 300 mg BID days 1–
7 (DL1), AZA 75 mg/m2 days 1–5 and VST 200 mg BID
days 1–7 (DL2), AZA 55 mg/m2 days 1–5 and VST
300 mg BID days 1–14 (DL3), and AZA 75 mg/m2 days
1–5 and VST 200 mg BID days 1–14 (DL4). Each cycle
was 28 days, and patients were treated for up to six cy-
cles. If at any time two patients in a given cohort experi-
enced dose-limiting toxicities (DLT), enrollment to that
level was discontinued. Up to eight patients were en-
rolled to each dose level, and accrual to the next dose
level was dependent on the toxicity and efficacy of the
previous dose levels. Each of these doses had been ex-
plored in phase I trials of myelodysplastic syndrome
(MDS), and all had been found to be tolerable.
Assessments
Tumor assessments were made with 18FDG-PET/CT
(fluorodeoxyglucose-18 positron emission tomography/
computed tomography) scans prior to the third cycle
and after the sixth cycle of treatment and CT scans were
planned at 3-monthly intervals during post-treatment
follow-up evaluations. Treatment responses were defined
according to the International Workshop Criteria (IWC)
[13] and the revised International Workshop Criteria
with integration of 18FDG-PET (IWC + PET) [14] and
classified as either complete response (CR), CR uncon-
firmed (CRu), partial response (PR), stable disease (SD),
or progressive disease (PD). Safety was assessed by ad-
verse events (AE) graded according to the National Can-
cer Institute Common Terminology Criteria for Adverse
Events version 4.0 with DLT defined as any of the fol-
lowing treatment-related AE during the first cycle of
treatment: grade 3–4 non-hematologic toxicity excluding
alopecia, nausea, vomiting, or fatigue responding to max-
imal treatment; any grade 4 hematological toxicity includ-
ing grade 4 neutropenia lasting longer than 7 days in the
setting of G-CSF use; failure of ANC to recover to >1000
cells/μL or platelets to recover to >50,000/μL within
14 days; and grade 4 thrombocytopenia of any duration.
Febrile neutropenia <grade 4 was not considered a DLT.
Statistical analysis
Safety data and response rates were summarized using
descriptive statistics. OS was calculated from date of
study entry to the time of death from any cause or the
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date of last follow-up. Data on patients alive at last
follow-up were censored during the survival analysis. A
post hoc review was performed on patients who received
other treatment after study discontinuation. Time to
progression (TTP post-study) was calculated from the
date off study to the date of progression and OS post-
study was calculated from the date off study to the date
of death or last follow-up.
Results
Vorinostat and decitabine combination shows synergistic
anti-lymphoma effect on DLBCLs
To perform combinatorial studies of epigenetic drugs in
relapsed DLBCL cell lines, we first determined the sensi-
tivity to vorinostat and decitabine in a panel of 27
DLBCL cell lines, 15 of them established at diagnosis (P-
DLBCL) and 12 of them established from relapsed pa-
tients after at least one line of treatment (R-DLBCL).
We have previously showed that R-DLBCL cell lines
remained resistant to at least one of the chemotherapy
agents included in the CHOP regimen (i.e., doxorubicin,
vincristine, mechlorethamine for cyclophosphamide, and
dexamethasone for prednisone) [7]. We exposed this
panel to vorinostat or decitabine for 48 h and deter-
mined their proliferation activity by a resazurin reduc-
tion assay. The administration of vorinostat or
decitabine reduced the proliferation of all tested cell
lines regardless their origin (Fig. 1a), suggesting that,
despite their origin, R-DLBCL are similarly sensitive to
these epigenetic drugs. We then selected five R-DLBCL
(OCI-Ly1, OCI-Ly7, WSU-NHL, Farage and Toledo)
and P-DLBCL (SU-DHL4) cell lines to determine the
anti-proliferative effect of the combination of vorinostat
with decitabine by calculating the CI [12]. Similar to in-
dividual drugs, the combination of vorinostat and decita-
bine was synergistic in all the R-DLBCL and P-DLBCL
cell lines tested (Fig. 1b).
To determine whether the combination of vorinostat
and decitabine is effective in R-DLBCL in vivo, we ad-
minister human-equivalent doses of vehicle, vorinostat
Fig. 1 Effect of the combination vorinostat with decitabine on DLBCL cells. a Scatter plots of the GI50 values of vorinostat (VST, left) and
decitabine (DAC, right) in a panel of 27 DLBCL cell lines obtained at initial diagnosis or at relapse. b Isobologram for Toledo, Farage, OCI-Ly1,
WSU-NHL, OCI-Ly7, and SU-DHL4, tested for the combination of DAC and VST. Circles represent each cell line with their relative position to the
additive line indicating the result from the combination. Cells below the line indicate a synergistic effect. c DLBCL tumor growth curves (shown
as area under the curve) in SU-DHL4 (left) and OCI-Ly7-xenografted (right) mice treated with vehicle, VST, DAC, or VST + DAC
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20 mg/kg/day, decitabine 15 mg/m2/day, or their com-
bination to mice bearing R-DLBCL OCI-Ly7 cell line xe-
nografts. We used P-DLBCL SU-DHL4 xenografts as
controls. When xenografts reached 75 to 100 mm3, the
mice were randomized in four groups and treated with
vehicle, decitabine, vorinostat, or the combination of
vorinostat + decitabine, daily for 11 and 17 days in OCI-
Ly7 and SU-DHL4 xenografts, respectively (Fig. 1c). The
mice were followed until untreated tumors reached
1500 mm3. Compared to the vehicle-treated mice, deci-
tabine or vorinostat alone significantly suppressed the
growth of R-DLBCL OCI-Ly7 and P-DLBCL SU-DHL4
xenografts. In both models, the combination of vorino-
stat + decitabine resulted in a significantly higher lymph-
oma control than either drug alone. There was no
evidence of toxicity to normal tissues based on body
weight and macroscopic examination of tissues at nec-
ropsy. Overall, these data suggest that the combination
of vorinostat and decitabine may be effective toward R-
DLBCL with no evidence of gross toxicity.
Phase Ib study of azacitidine and vorinostat in patients
with relapsed or refractory DLBCL
The promising results observed in pre-clinical model
prompted us to perform a phase Ib study (Table 1) to
evaluate the combination of the DNA methyltransferase
inhibitor azacitidine and the histone deacetylase inhibi-
tor vorinostat. Subjects with RR-DLBCL ineligible (due
to chemorefractory state or comorbidities) or relapsed
after autologous stem cell transplant were treated with
azacitidine and vorinostat at four different dose levels
(DL). A total of 18 patients were enrolled (Table 2). The
median age was 66 years old. The subjects had received
a median of 3 prior lines of treatment, including three
that had undergone autologous stem cell transplantation.
Thirteen patients were refractory to their previous treat-
ment. Eight patients were treated at dose level 1 (DL1),
five at DL2, four at DL3, and one at DL4. DL3 and DL4
were closed early after two patients at DL3 required
dose reductions. A median of two cycles (range 1–6) of
treatment was administered. One patient completed 6 cy-
cles of treatment, and 17 patients stopped treatment due
to PD. The trial was terminated prematurely because of
low clinical activity and poor tolerability at the doses/
schedules tested in this study.
The following grade 1–2 hematological and non-
hematologic toxicities, independent of relation to study
drugs, were experienced by at least two subjects: anemia
(n = 14), thrombocytopenia (n = 6), leucopenia (n = 5),
neutropenia (n = 2), nausea (n = 12), hypoglycemia (n =
7), renal impairment (n = 7), diarrhea (n = 6), vomiting
(n = 6), raised ALP (n = 5), hyperglycemia (n = 5), fa-
tigue (n = 4), fever (n = 3), and hyperbilirubinemia (n =
3). One patient experienced a grade 3 thromboembolism
at DL1, one experienced grade 3 diarrhea at DL2, and
one experienced grade 4 increase in ALP at DL4. Grade
3–4 hematologic toxicity included thrombocytopenia (n
= 8), anemia (n = 3), and neutropenia (n = 2) (Additional
file 1: Table S1). Only one DLT occurred at DL1 as a re-
sult of grade 4 thrombocytopenia.
At DL1, two subjects had SD, five had PD, and re-
sponse status was not evaluable in two patients. At DL2,
one subject had a PR, one had SD, and three had PD. At
DL3, three had PD, and response status was not evalu-
able in one. The only subject treated at DL4 had PD
(Additional file 2: Table S2). Hence, the ORR was 6.7 %
(1/15), and 86.7 % (13/15) had PD in evaluable subjects.
The 3-month OS for the entire cohort was 77 % (95 %
CI 34–94 %).
Clinical follow-up suggests a potential chemosensitization
effect of the combination of DNMTI and HDI
Seven subjects enrolled in the phase Ib study received
further treatment. Prior to enrolling in the trial, two
Table 1 Overview of the phase Ib study on the combination of vorinostat and azacitidine in RR-DLBCL patients
Open-label phase Ib (NCT01120834)
Key enrollment criteria Dose level 1 Key endpoints Post-study
R/R-DLBCL AZA 55 mg/m2 s.q. D 1 to 5 Primary:
MTD or MAD
ORR and subsequent OS
VST 300 mg/m2 BID D 1 to 7
Relapsed after or ineligible for ASCT Dose level 2
ANC > or = 1000/μL AZA 75 mg/m2 s.q. D 1 to 5 Secondary:
Efficacy
VST 200 mg/m2 BID D 1 to 7
Platelets > or = 75/μL Dose level 3
Adequate renal and hepatic functions AZA 55 mg/m2 s.q. D 1 to 5
VST 300 mg/m2 BID D 1 to 14
No prior treatment with HDACIs Dose level 4
QTc no more than 0.470 AZA 75 mg/m2 s.q. D 1 to 5
VST 200 mg/m2 BID D 1 to 14
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patients had relapsed disease and five had disease that
was refractory to last pre-study therapy. These subjects
received a median of two cycles of azacitidine and vori-
nostat. Subsequent therapies included veltuzumab radio-
immunotherapy (n = 1), oral PEP-C (procarbazine,
etoposide, prednisone, cyclophosphamide; n = 2), bren-
tuximab vedotin-PEP-C (n = 1), and RDICE (rituximab,
dexamethasone, ifosfamide, cisplatin, etoposide) followed
by allogeneic stem cell transplantation (n = 1) and bend-
amustine (n = 2).
Although one of the two patients that received benda-
mustine achieved significant clinical benefit, the short
follow-up of both patients limited any conclusion based
on these two cases. For the other five patients that re-
ceived post-trial treatments, two patients had a CR and
two others had a significant clinical benefit (Table 3). At
the time of data collection, the OS post-study in these
five patients ranged from 79 to 825 days. Despite these
promising responses, all four deaths were due to pro-
gressive lymphoma. Taking into account the fact that the
majority of these patients had disease that was refractory
to the last therapy, these data suggest that combination
of vorinostat and azacitidine, although providing only
marginal disease control during administration, was as-
sociated with a delayed chemosensitization effect.
The chemosensitization effect of the DNMTI and HDI
combination is largely due to the DNMTI
The above observation is in general agreement with our
previous demonstration that DNMTI can induce repro-
gramming of chemorefractory DLBCL cell lines resulting
in a p21-associated senescence-like phenotype and che-
mosensitization [7]. In the light of the clinical observa-
tion of these seven patients, and in order to determine
whether the combination of DNMTI and HDI could in-
duce a higher chemosensitizing effect than DNMTI
alone, we determined the induction of p21 in OCI-Ly1
cells treated with decitabine, vorinostat or their combin-
ation. The combination of vorinostat and decitabine in-
duced a mild increase in p21 over single agent
administration (Fig. 2a). This effect was insufficient to
increase the chemosensitizing effect of the combination
vs. each drug alone to mechlorethamine and doxorubicin
(Fig. 2b). In fact, only decitabine administration induced
significant chemosensitization to both agents (Fig. 2b).
To further explore this effect, we implanted R-DLBCL
OCI-Ly7 cells into SCID mice as before. When tumors
developed, the mice were randomized into four groups
and treated with vehicle (n = 8), decitabine (n = 5), vori-
nostat (n = 5), or the combination vorinostat + decita-
bine (n = 5), daily for 6 days. At day 7 and day 13, the
mice received a dose of doxorubicin equivalent to the
human dose for the treatment of lymphomas (0.6 mg/
kg) (Fig. 2c). Compared to the mice that received vehicle
followed by doxorubicin, the mice pre-treated with the
combination of vorinostat and decitabine and the mice
pre-treated with decitabine alone showed significant
tumor control (P = 0.0003 and P = 0.0004, respectively).
However, tumor growth in the mice that received vori-
nostat followed by doxorubicin were undistinguishable
from those that received vehicle followed by doxorubicin
(P = 0.556). Moreover, there was no difference in the de-
gree of chemosensitization in mice receiving combin-
ation pre-treatment vs. the decitabine single agent pre-
treatment (P = 0.201), suggesting that the chemosensitiz-
ing effect observed in the pre-clinical model, and poten-
tially in patients, with the combination of vorinostat and
decitabine is likely due to decitabine administration.
Discussion
The aim of our studies was to determine whether the
combination of the epigenetic drugs azacitidine and vor-
inostat was safe and potentially active in RR-DLBCL pa-
tients. We also aimed to evaluate in pre-clinical models
whether addition of vorinostat could potentiate the che-
mosensitizing effect of DNMTIs previously reported by
our group [7]. In agreement with previous reports [15],
Table 2 Baseline clinical characteristics of the subjects enrolled
into the study













Transformed FL 2 11.1
CLL with Richter’s transformation 1 5.5
Prior treatments regimens
Median (range) 3 (1–4)
Rituximab-containing 18 100
Autologous stem cell transplantation 3 16.7
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vorinostat and decitabine showed synergistic anti-
lymphoma effect in DLBCL cell lines in vitro and in
vivo. However, a similar combination evaluated in pa-
tients with RR-DLBCL was poorly tolerated and had a
minimal clinical activity.
Similar studies have been performed in other
hematologic malignancies [16–21]. A phase I study in-
vestigated the combination of decitabine and vorinostat
in concurrent and sequential arms in 71 AML and MDS
patients resulted in promising results but relatively high
incidence of drug-related adverse events [16]. In the
concurrent arm, which more closely mirrors the design
of our study, hematologic toxicities occurred more fre-
quently than in the sequential arm [16]. In our study,
the incidence of hematological side effects was 94 % for
all grades of anemia, 78 % for thrombocytopenia, 50 %
for leucopenia, and 20 % for neutropenia. The higher
rates of hematological side effects in our study are likely
a reflection of a more heavily pre-treated cohort of
patients. In another study, 40 patients with MDS were
enrolled into a phase II study that tested azacitidine at
55–75 mg/m2 and vorinostat at 200–300 mg BID for 7–
14 days at three dose levels [17]. In this study, a median
of 6 cycles were administered (range 1–26), and grade 3
fatigue occurred in 32 % of patients while no grade 3 fa-
tigue occurred in our study and this could be due to the
fewer number of treatment cycles administered. In sum-
mary, we consider that combination of HDIs with
DNMTIs shows limited activity in the population of pa-
tients treated in our study. Nevertheless, we consider
that this combination merits further investigations in
DLBCL patients with less pre-treated disease.
Despite good pre-clinical data to support the combin-
ation of azacitidine or decitabine with vorinostat, clinical
responses have been dismal. One explanation for the poor
clinical response observed is that the patients chosen for
these clinical trials had aggressive tumors with high tumor
burden that did not allow enough time for the epigenetic
agents to act. In this regard, epigenetic therapy combina-
tions with the more potent drug decitabine (instead of
azacitidine) or longer administration time, for example,
with oral version of these hypomethylating agents,
could be worth exploring. However, our previous ex-
perience in pre-clinical models and front-line DLBCL
Table 3 Follow-up details of subjects who had further treatment after the phase Ib study















































PD NA 2 Brentuximab +
PEP-C (×4)





PD NA 4 RDICE (×3),
ASCT













PD NA 1 Bendamustine
(×1)
4 NA NA 35 Alive
Time to progression and overall survival calculated from the time the subject was taken off the study
RCHOP rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone, VIPER bortezomib in combination with DICE chemotherapy
plus rituximab, BEAM combination of carmustine, etoposide, cytarabine, and melphalan, ASCT autologous stem cell transplant, RT radiotherapy, RHCVAD rituximab-
fractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone, ESHAP etoposide, methylprednisolone, cytarabine and cisplatin, RCIE rituximab, ifosfamide,
carboplatin, and etoposide, CR complete remission, PD progressive disease, NA not available, PEP-C prednisone, etoposide, procarbazine, and cyclophosphamide, TTP
time to progression, OS overall survival
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patients treated with azacitidine suggested that tumor
reduction might not be the optimal criteria to evalu-
ate the antineoplastic effect of epigenetic drugs. While
cellular reprogramming seems to be the dominant
effect of these drugs on pre-clinical models [7], a vali-
dated clinical biomarker is still lacking.
Supporting the role of epigenetic drugs as chemosensiti-
zers, we observed a potential delayed chemosensitizing
Fig. 2 Chemosensitizing effect of the combination vorinostat with decitabine. a Treatment schedule performed in OCI-Ly1 cells receiving vorinostat
(VST) and decitabine (DAC) followed by doxorubicin (Doxo) or mechlorethamine (Mechlo) (upper part), and mRNA and protein levels of p21 after 5 days
of treatment (lower part). b Reduction in the growth inhibition 50 (GI50) values for mechlorethamine and doxorubicin after treatment with the VST and
DAC combination. c Treatment schedule for mice receiving vehicle, VST, DAC, or VST + DAC, followed by doxorubicin (left part). On the right part, area
under the curve (AUC) of tumor growth curves in OCI-Ly7-treated xenografts. d Representative images from OCI-Ly7 mice tumors after being treated,
assayed for apoptosis by TUNEL. The percentages of stained area (mean ± the standard error) are shown at the bottom. The bar represents 100 μm
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effect of azacitidine and vorinostat combination in seven
patients enrolled in our study. Although five of these pa-
tients had disease refractory to several prior lines of ther-
apy and all seven progressed on the study regimen, two
patients had a complete response to subsequent treatment
while three others had a significant clinical benefit. Fur-
ther cellular and mice studies suggested that this effect
could be consequence of the DNMTI rather than to the
combination, since the addition of vorinostat to decitabine
did not increase significantly the chemosensitizing effect
of decitabine alone. Caution should be exercised when
interpreting these results. The number of patients in-
cluded in this experience is small, and the patients were
heterogeneous with respect to their response to treat-
ments administered before and after the clinical trial. Pa-
tients that appeared to derive the most benefit from
azacitidine priming could have been those with less ag-
gressive or more chemosensitive disease. Similarly, given
the differences in duration of exposure to the study drugs
and intensity of post-treatment therapy, it is not possible
to extrapolate our experience to optimize the sequencing
of DNMTI and chemotherapeutic agent. Also, a signifi-
cant potential for increased toxicity exists, particularly
when DNMTI is administered with potent alkylating
agents, and we do not recommend using this approach
outside the context of a clinical trial. Nonetheless, our re-
sults suggest that epigenetic priming with DNMTI could
be a potential therapeutic approach for RR-DLBCL pa-
tients in order to overcome chemotherapy resistance and
improve their outcomes. Thus, further clinical trials are
needed to confirm the value of such strategy.
Conclusions
In sum, we demonstrated that combination of HDI and
DNMTI has synergistic activity in vitro and exhibits higher
antitumor activity than single agents in vivo in DLBCL pre-
clinical models. However, the combination of azacitidine
and vorinostat in RR-DLBCL patients showed limited clin-
ical activity. Post-trial follow-up of some of these patients
and in vivo murine models suggested a sensitizing effect of
the combination to subsequent therapies. In further pre-
clinical studies, we demonstrated that DNMTI is likely the
main contributor to this effect in DLBCL.
Additional files
Additional file 1: Table S1. Toxicity. Highest grade of treatment-
emergent adverse events encountered at the four different dose levels. (DLs).
DL1: azacitidine (AZA) 55 mg/m2 days 1–5 and vorinostat (VST) 300 mg BID
days 1–7. DL2: AZA 75 mg/m2 days 1–5 and VST 200 mg BID days 1–7. DL3:
AZA 55 mg/m2 days 1–5 and VST 300 mg BID days 1–14. DL4: AZA 75 mg/
m2 days 1–5 and VST 200 mg BID days 1–14. (DOC 57.0 kb)
Additional file 2: Table S2. Treatment response at the four different
dose levels (DLs). DL1: Azacitidine (AZA) 55 mg/m2 days 1–5 and
vorinostat (VST) 300 mg BID days 1–7. DL2: AZA 75 mg/m2 days 1–5 and
VST 200 mg BID days 1–7. DL3: AZA 55 mg/m2 days 1–5 and VST
300 mg BID days 1–14. DL4: AZA 75 mg/m2 days 1–5 and VST 200 mg
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